JPS4910506A
(pl)
|
1972-05-31 |
1974-01-30 |
|
|
US4582909A
(en)
|
1984-02-02 |
1986-04-15 |
Warner-Lambert Company |
Benzobicyclic lactam acids and derivatives as cognition activators
|
US4666828A
(en)
|
1984-08-15 |
1987-05-19 |
The General Hospital Corporation |
Test for Huntington's disease
|
US4760064A
(en)
|
1984-12-18 |
1988-07-26 |
Otsuka Pharmaceutical Co., Ltd. |
Carbostyril compounds, compositions containing same and processes for preparing same
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
US4801531A
(en)
|
1985-04-17 |
1989-01-31 |
Biotechnology Research Partners, Ltd. |
Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
|
CA1340191C
(en)
|
1988-06-13 |
1998-12-15 |
Katsuhiro Imaki |
Derivatives of p-substituted phenyl ester of pivalic acid
|
US4990511A
(en)
|
1988-08-03 |
1991-02-05 |
Takeda Chemical Industries, Ltd. |
Amide compounds, their production and use
|
US5272057A
(en)
|
1988-10-14 |
1993-12-21 |
Georgetown University |
Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
|
US5192659A
(en)
|
1989-08-25 |
1993-03-09 |
Genetype Ag |
Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
|
GB8926560D0
(en)
|
1989-11-24 |
1990-01-17 |
Zambeletti Spa L |
Pharmaceuticals
|
US5124350A
(en)
|
1990-06-28 |
1992-06-23 |
G. D. Searle & Co. |
Leukotriene b4 antagonists
|
ZA916555B
(en)
|
1990-08-27 |
1993-04-28 |
Lilly Co Eli |
Method of treating inflammatory bowel disease
|
FR2669029B1
(fr)
|
1990-11-14 |
1994-09-02 |
Adir |
Nouveaux derives de la n-benzoyl proline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
|
US5280046A
(en)
|
1991-02-22 |
1994-01-18 |
The University Of Colorado Foundation, Inc. |
Method of treating type I diabetes
|
WO1992017467A1
(en)
|
1991-04-06 |
1992-10-15 |
Dr Lo. Zambeletti S.P.A. |
Substituted azacyclic compounds, process for their preparation and their use as analgesics
|
US5633283A
(en)
|
1995-01-23 |
1997-05-27 |
Eli Lilly And Company |
Method for treating multiple sclerosis
|
CA2262403C
(en)
|
1995-07-31 |
2011-09-20 |
Urocor, Inc. |
Biomarkers and targets for diagnosis, prognosis and management of prostate disease
|
US6218529B1
(en)
|
1995-07-31 |
2001-04-17 |
Urocor, Inc. |
Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
|
JP3855026B2
(ja)
|
1996-01-16 |
2006-12-06 |
富士レビオ株式会社 |
アミド誘導体の製造方法
|
WO1997026884A1
(en)
|
1996-01-29 |
1997-07-31 |
The Regents Of The University Of California |
Method for treating sexual dysfunctions
|
GB9606187D0
(en)
|
1996-03-23 |
1996-05-29 |
Inst Of Food Research |
Production of vanillin
|
AU715658B2
(en)
|
1996-04-03 |
2000-02-10 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
WO1997039750A1
(en)
|
1996-04-19 |
1997-10-30 |
The Regents Of The University Of California |
Treatment of mood/affective disorders by glutamatergic upmodulators
|
IL118657A0
(en)
|
1996-06-14 |
1996-10-16 |
Arad Dorit |
Inhibitors for picornavirus proteases
|
JP2001514631A
(ja)
|
1997-03-07 |
2001-09-11 |
ノボ ノルディスク アクティーゼルスカブ |
4,5,6,7−テトラヒドロ−チエノ[3,2−c]ピリジン誘導体類、それらの製造方法及び使用
|
UY24949A1
(es)
|
1997-04-08 |
2001-04-30 |
Smithkline Beecham Corp |
Compuestos calcilíticos
|
JP2001526643A
(ja)
|
1997-04-18 |
2001-12-18 |
スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー |
5ht1a、5ht1bおよび5ht1d受容体アンタゴニスト活性を合わせ持つ化合物を含む二環式アリールまたは二環式複素環
|
US6329368B1
(en)
|
1997-05-09 |
2001-12-11 |
The Regents Of The University Of California |
Endocrine modulation with positive modulators of AMPA type glutamate receptors
|
AU745641B2
(en)
|
1997-10-27 |
2002-03-28 |
Cortex Pharmaceuticals, Inc. |
Treatment of schizophrenia with ampakines and neuroleptics
|
AU1804299A
(en)
|
1997-12-08 |
1999-06-28 |
Glycomed Incorporated |
Sialyl lewis x and sialyl lewis a glycomimetics
|
WO2000059867A1
(en)
|
1999-03-30 |
2000-10-12 |
Pharmacor Inc. |
Hydroxyphenyl derivatives with hiv integrase inhibitory properties
|
DE19955283A1
(de)
|
1999-11-17 |
2001-05-23 |
Aventis Res & Tech Gmbh & Co |
Verfahren zur enantioselektiven Gewinnung von Aminosäuren und Aminosäurederivaten unter Verwendung von Racemisierungskatalysatoren
|
US6677473B1
(en)
|
1999-11-19 |
2004-01-13 |
Corvas International Inc |
Plasminogen activator inhibitor antagonists
|
WO2001060369A1
(en)
|
2000-02-18 |
2001-08-23 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
AU5959201A
(en)
|
2000-05-11 |
2001-11-20 |
Bristol Myers Squibb Co |
Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
|
WO2001087834A1
(fr)
|
2000-05-16 |
2001-11-22 |
Takeda Chemical Industries, Ltd. |
Antagoniste de l'hormone de concentration de la melanine
|
CA2308994A1
(en)
|
2000-05-19 |
2001-11-19 |
Aegera Therapeutics Inc. |
Neuroprotective compounds
|
DE10024939A1
(de)
|
2000-05-19 |
2001-11-29 |
Bayer Ag |
Neue Diphenylmethanderivate für Arzneimittel
|
FR2812876B1
(fr)
|
2000-08-08 |
2002-09-27 |
Galderma Res & Dev |
Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
|
YU14303A
(sh)
|
2000-08-25 |
2006-08-17 |
Warner Lambert Company Llc. |
Postupak pripremanja n-aril antranilnih kiselina i njihovih derivata
|
US8263657B2
(en)
|
2000-12-18 |
2012-09-11 |
Institute Of Medicinal Molecular Design, Inc. |
Inhibitors against the production and release of inflammatory cytokines
|
WO2003041641A2
(en)
|
2001-11-09 |
2003-05-22 |
Bristol-Myers Squibb Company |
Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
|
AU2002366362A1
(en)
|
2001-12-18 |
2003-06-30 |
Bayer Aktiengesellschaft |
2-substituted pyrrolo(2.1-a)isoquinolines against cancer
|
JP4440642B2
(ja)
|
2001-12-20 |
2010-03-24 |
オーエスアイ・ファーマスーティカルズ・インコーポレーテッド |
ピリミジンA2b選択的アンタゴニスト化合物、それらの合成、及び使用
|
AU2002356301A1
(en)
|
2001-12-21 |
2003-07-15 |
Cancer Research Technology Ltd. |
3,4-diarylpyrazoles and their use in the therapy of cancer
|
CA2480832A1
(en)
|
2002-04-05 |
2003-10-23 |
Nitromed, Inc. |
Nitric oxide donors, compositions and methods of use
|
WO2003103658A1
(ja)
|
2002-06-05 |
2003-12-18 |
株式会社医薬分子設計研究所 |
免疫関連プロテインキナーゼ阻害剤
|
CN100379410C
(zh)
|
2002-06-05 |
2008-04-09 |
株式会社医药分子设计研究所 |
糖尿病治疗药
|
CA2487891A1
(en)
|
2002-06-05 |
2003-12-18 |
Institute Of Medicinal Molecular Design, Inc. |
Inhibitors against the activation of ap-1 and nfat
|
CA2488367A1
(en)
|
2002-06-06 |
2003-12-18 |
Institute Of Medicinal Molecular Design, Inc. |
Antiallergic agents
|
SE0202133D0
(sv)
|
2002-07-08 |
2002-07-08 |
Astrazeneca Ab |
Novel compounds
|
NZ537853A
(en)
|
2002-07-16 |
2007-02-23 |
Amura Therapeutics Ltd |
Inhibitors of cathepsin K and related cysteine protesases of the CA clan
|
US20050215614A1
(en)
|
2002-10-15 |
2005-09-29 |
Rigel Pharmaceuticals, Inc. |
Substituted indoles and their use as hcv inhibitors
|
TWI228885B
(en)
|
2003-01-23 |
2005-03-01 |
Mediatek Inc |
Method for controlling a mobile communication device to enter a power-saving mode and to recover timing after the mobile communication device leaves the power-saving mode
|
CN1771235B
(zh)
|
2003-02-11 |
2010-04-28 |
弗奈利斯(剑桥)有限公司 |
异噁唑化合物
|
CN1764375A
(zh)
|
2003-02-20 |
2006-04-26 |
康涅狄格大学健康中心 |
使用包括热休克蛋白或α-2-巨球蛋白的组合物治疗癌症和传染病的方法
|
EP1597256A1
(en)
|
2003-02-21 |
2005-11-23 |
Pfizer Inc. |
N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors
|
EP1622866B1
(en)
|
2003-04-30 |
2012-07-25 |
Novartis AG |
Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators
|
ES2432747T3
(es)
|
2003-06-27 |
2013-12-05 |
Kyowa Hakko Kirin Co., Ltd. |
Inhibidores de proteínas de la familia HSP90
|
GB0315111D0
(en)
|
2003-06-27 |
2003-07-30 |
Cancer Rec Tech Ltd |
Substituted 5-membered ring compounds and their use
|
TWI322806B
(en)
|
2003-06-30 |
2010-04-01 |
Mitsubishi Tanabe Pharma Corp |
Process of preparating 3-acylaminobenzofuran-2-carboxylic acid derivatives
|
CA2532313A1
(en)
|
2003-07-16 |
2005-01-27 |
Institute Of Medicinal Molecular Design. Inc. |
Medicament for treatment of dermal pigmentation
|
WO2005012256A1
(en)
|
2003-07-22 |
2005-02-10 |
Astex Therapeutics Limited |
3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
|
US7977387B2
(en)
|
2003-07-24 |
2011-07-12 |
Leo Pharma A/S |
Aminobenzophenone compounds
|
PT1660492E
(pt)
|
2003-07-28 |
2008-11-13 |
Janssen Pharmaceutica Nv |
Derivados de benzimidazole, benzotiazole e benzoxazole e sua utilização como moduladores de lta4h
|
DE10335584B4
(de)
|
2003-07-31 |
2006-06-29 |
Philipps-Universität Marburg |
Verfahren zur Herstellung zyklischer Moleküle
|
DE10335726A1
(de)
|
2003-08-05 |
2005-03-03 |
Bayer Cropscience Gmbh |
Verwendung von Hydroxyaromaten als Safener
|
WO2005016889A1
(en)
|
2003-08-08 |
2005-02-24 |
Virginia Commonwealth University |
Compounds having antiestrogenic and tissue selective estrogenic properties
|
AU2004270394A1
(en)
|
2003-09-10 |
2005-03-17 |
Gpc Biotech Ag |
Heterobicyclic compounds as pharmaceutically active agents
|
CA2543913A1
(en)
|
2003-11-10 |
2005-05-26 |
Schering Aktiengesellschaft |
Benzylether amine compounds useful as ccr-5 antagonists
|
EP1704856A4
(en)
|
2003-12-26 |
2009-08-19 |
Kyowa Hakko Kirin Co Ltd |
PROTEIN INHIBITOR OF THE HSP90 FAMILY
|
US7351709B2
(en)
|
2004-06-09 |
2008-04-01 |
Wyeth |
Estrogen receptor ligands
|
CA2573362A1
(en)
|
2004-07-27 |
2006-02-09 |
Sgx Pharmaceuticals, Inc. |
Pyrrolo-pyridine kinase modulators
|
WO2006023778A2
(en)
|
2004-08-20 |
2006-03-02 |
The Regents Of The University Of Michigan |
Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof
|
DE102004049078A1
(de)
|
2004-10-08 |
2006-04-13 |
Merck Patent Gmbh |
Phenylpyrazole
|
US7208630B2
(en)
|
2004-10-27 |
2007-04-24 |
University Of Kansas |
Heat shock protein 90 inhibitors
|
WO2006051808A1
(ja)
|
2004-11-09 |
2006-05-18 |
Kyowa Hakko Kogyo Co., Ltd. |
Hsp90ファミリー蛋白質阻害剤
|
DK1848694T3
(da)
|
2005-02-07 |
2010-01-25 |
Hoffmann La Roche |
Heterocykliske substituerede phenylmethanoner som inhibitorer af glycintransporter
|
US20060183902A1
(en)
|
2005-02-15 |
2006-08-17 |
Baxter Ellen W |
Dihydroindolyl methanones as alpha 1a/1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms
|
BRPI0608216A2
(pt)
|
2005-02-21 |
2009-11-24 |
Kyowa Hakko Kogyo Kk |
agente terapêutico para um tumor, método para tratar um tumor, e, uso de um composto de benzoìla, uma pró-groga do mesmo ou um sal farmaceuticamente aceitável do mesmo
|
MX2007012659A
(es)
|
2005-04-13 |
2008-01-11 |
Astex Therapeutics Ltd |
Derivados de hidroxi-benzamida y su uso como inhibidores de hsp90.
|
US20090215742A1
(en)
|
2005-05-03 |
2009-08-27 |
Pfizer, Inc. |
Amide resorcinol compounds
|
US7425633B2
(en)
|
2005-08-26 |
2008-09-16 |
National Health Research Institutes |
Pyrrolidine compounds
|
US7754725B2
(en)
|
2006-03-01 |
2010-07-13 |
Astex Therapeutics Ltd. |
Dihydroxyphenyl isoindolymethanones
|
EP2073804B1
(en)
|
2006-10-12 |
2017-09-13 |
Astex Therapeutics Limited |
Hydroxy-substituted benzoic acid amide compounds for use in the treatment of pain
|
US8916552B2
(en)
|
2006-10-12 |
2014-12-23 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
GB0620259D0
(en)
|
2006-10-12 |
2006-11-22 |
Astex Therapeutics Ltd |
Pharmaceutical compounds
|
EP2073807A1
(en)
|
2006-10-12 |
2009-07-01 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
JP5410285B2
(ja)
*
|
2006-10-12 |
2014-02-05 |
アステックス、セラピューティックス、リミテッド |
医薬化合物
|
WO2008044029A1
(en)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|